Through its ability to access the scientific and technical resources of B D Forrest & Company, Inc., Aeolian Advisors is able to provide a higher level of granularity in the analyses that address the scientific and technical aspects of any specific investment opportunity in this space helping to provide an additional assessment of risk and probability of success of the particular opportunity’s portfolio.

Scientific and technical due diligence provides a critical function in the decision-making concerning the investment decisions involving these small & emerging growth biotechnology and medical device companies. Not simply financial due diligence, but also scientific, technical, and regulatory (pharmaceutical and medical device), as the quality of the underlying intellectual property, stage of development, drug or device approval pathway, emerging safety and/or efficacy profile or sensitivity/specificity, being able to estimate the position of the opportunity within the greater healthcare market, and pharmaceutical and medical device development experience of key management, can all significantly affect the valuation and probability of an eventual return on the investment.